IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Nasopharyngeal Carcinoma Clinical Trial

Official title:

A Single Center 、Single Arm Phase I/II Clinical Trial of Intensity-modulated Radiotherapy Combined With Toripalimab in the Treating of Unresectable Locally Recurrent Nasopharyngeal Carcinoma.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03854838
• Other study ID #: 2019-FXY-020
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 1, 2019
• Est. completion date: February 1, 2023

Study information

• Verified date: April 2022
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of intensity-modulated radiation therapy combined with toripalimab in patients with the unresectable locally recurrent nasopharyngeal carcinoma.

Description:

This is an open-label ,single center ,non-randomized, single arm exploratory study. All eligible patients presented with non-keratinizing NPC and stage rT0-4N1-3M0 /rT2-4N0M0 are assigned to receive IMRT combined with toripalimab.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: February 1, 2023
• Est. primary completion date: February 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Histologically confirmed Recurrent Nasopharyngeal Carcinoma ( the recurrence time was more than 12 months from the end of the first course of radiotherapy)

2. Patients with histologically confirmed nasopharyngeal carcinoma(WHO type II-III)

3. Subjects must have measurable disease by CT or MRI per RECIST 1.1 criteria;

4. Can provide either a newly obtained or archival tumor tissue sample.

5. Tumor staged as rT0-4N1-3M0 or T2-4N0M0,II-IVa (according to the 8th AJCC edition).

6. 18 Years to 65 Years

7. Eastern Cooperative Oncology Group performance status =1

8. Adequate marrow function: neutrocyte count=1.5×10e9/L, hemoglobin =90g/L and platelet count =100×10e9/L.Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) =2.5×upper limit of normal (ULN), and bilirubin = 1.5×ULN. Adequate renal function: creatinine clearance rate = 60 ml/min (Cockcroft-Gault formula).

9. Life expectancy = 3months

10. Subjects must be willing to participate in the research and sign an informed consent form (ICF)

11. Female of child bearing potential, a negative urine or serum pregnancy test result within 72 h before study treatment. Participants of reproductive potential must be willing to use adequate contraception for the course of the study through 60 days after the last dose of Toripalimab.

12. Male subjects with WOCBP partner must be willing to use adequate contraception for the course of the study through 120 days after the last dose of Toripalimab.

Exclusion Criteria:

1. operable recurrence of nasopharyngeal cancer: rT1N0M0 rT2N0M0 (the tumour was confined in the superficial parapharyngeal spacer) rT3N0M0 (the tumour was confined in the base wall of the sphenoid sinus) rT0N1-3M0 (the tumour was not invasion into the cervical vertebrae, brachial plexus, deep muscles of the neck, or carotid artery)

2. Has known allergy to large molecule protein products or any compound of study therapy

3. Has known Subjects with other malignant tumors

4. Has any active autoimmune disease or history of autoimmune disease

5. Has a history of psychiatric substance abuse, alcoholism, or drug addiction;

6. the laboratory examination value does not meet the relevant standards within 7 days before enrollment

7. Received a systematic Glucocorticoid therapy within 4 weeks of the first dose of study medication.

8. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year.

9. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent;

10. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy) Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll.

11. Has a known history of human immunodeficiency virus (HIV).

12. Has hepatitis B surface antigen (HBsAg) positive or hepatitis C virus (HCV) antibody positive

13. Has received a live vaccine within 4 weeks of planned start of study therapy

14. Pregnancy or breast feeding

Related Conditions & MeSH terms

• Carcinoma
• Head and Neck Neoplasm
• Head and Neck Neoplasms
• Nasopharyngeal Carcinoma
• Nasopharyngeal Diseases
• Nasopharyngeal Neoplasms
• Neoplasms

Intervention

Drug:
• Tolipalimab
Radiation begun the day after the first dose of Toripalimab. Toripalimab (240mg dose every 3 weeks for 7 cycles, one cycle is three weeks) will be administered as an intravenous infusion over 60 minutes.

Radiation:
• Reirradiation
intensity-modulated radiation therapy (IMRT), 60 Gy 2.2Gy per fraction ,5 fractions per week, for 6 weeks

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ORR	Objective Response Rate	Through study completion, an average of 1 year
Secondary	PFS	Progression-Free Survival is defined as time interval from recruitment to tumor progression or censoring.	up to 3 years
Secondary	OS	Overall Survival is defined as time interval from recruitment to all-caused death or censoring.	up to 3 years
Secondary	Incidence of Treatment-Emergent Adverse Events	Adverse events (AE), Serious Adverse Event(SAE)	Through study completion, an average of half a year